Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Utility weights according to NYHA subclass obtained from the systematic review

From: Cost-utility of ferric carboxymaltose (Ferinject®) for iron-deficiency anemia patients with chronic heart failure in South Korea

Source Respondents Assessment method Utilities by NYHA subclass Remarks
Fox 2007 [21] Not primary utility study - 0.93 0.78 0.61 0.44 Base case
Kirsch and McGuire 2000 [22] General population, UK TTO with EQ5D 0.934 0.782 0.553 0.371 2-year TTO
0.930 0.765 0.509 0.284 10-year TTO
0.932 0.774 0.531 0.328 Mean, sensitivity analysis
Lewis 2001 [23] Advanced CHF (EF < 40) patients, USA TTO, SG, MLWHF and VAS 0.97 0.80 0.65 0.30 Sensitivity analysis
Calvert 2005 [24] Patients requiring CRT (NYHA classes III and IV) from the CARE-HF trial, multi-country EQ-5D and MLWHF - - 0.61 0.44 Sensitivity analysis
Göhler 2009 [25] CHF patients in post AMI from the EPHESUS trial, multi-country EQ-5D 0.9 0.84 0.74 0.6 Utility in the absence of further comorbidities
  1. AMI, acute myocardial infarction; CARE-HF, Cardiac Resynchronization in Heart Failure; CHF, chronic heart failure; CRT, cardiac resynchronization therapy; EF, ejection fraction; EPHESUS, Eplerenone Post-acute Myocardial Infarction Heart Failure Efficacy and Survival Study; EQ-5D, EuroQol-5 dimension; MLWHF, Minnesota Living with Heart Failure questionnaire; TTO, time trade-off.
  2. The results from the study of Kirsch and McGuire (2000) [21] were used as utilities for NYHA classes I and II, and the results from the study of Calvert et al. (2005) [23] were used as utilities for NYHA classes III and IV.
  3. This result is not valid because our study population was defined as CHF patients with iron deficiency anemia.